Cargando…
COVID-19 and Liver Dysfunction: Current Insights and Emergent Therapeutic Strategies
The outbreak of coronavirus disease 2019 (COVID-19), caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has attracted increasing worldwide attention. Cases of liver damage or dysfunction (mainly characterized by moderately elevated serum aspartate aminotransferase levels) ha...
Autores principales: | Feng, Gong, Zheng, Kenneth I., Yan, Qin-Qin, Rios, Rafael S., Targher, Giovanni, Byrne, Christopher D., Poucke, Sven Van, Liu, Wen-Yue, Zheng, Ming-Hua |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
XIA & HE Publishing Inc.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7132016/ https://www.ncbi.nlm.nih.gov/pubmed/32274342 http://dx.doi.org/10.14218/JCTH.2020.00018 |
Ejemplares similares
-
Non-invasive fibrosis assessment in non-alcoholic fatty liver disease
por: Rios, Rafael S., et al.
Publicado: (2020) -
Associations of Hydroxysteroid 17-beta Dehydrogenase 13 Variants with Liver Histology in Chinese Patients with Metabolic-associated Fatty Liver Disease
por: Liu, Wen-Yue, et al.
Publicado: (2021) -
Association and Interaction Between Serum Interleukin-6 Levels and Metabolic Dysfunction-Associated Fatty Liver Disease in Patients With Severe Coronavirus Disease 2019
por: Gao, Feng, et al.
Publicado: (2021) -
Old and new classes of glucose-lowering agents as treatments for non-alcoholic fatty liver disease: A narrative review
por: Miao, Lei, et al.
Publicado: (2022) -
Current and emerging therapeutic strategies for Fanconi anemia
por: Shukla, Pallavi, et al.
Publicado: (2012)